1. JCO Precis Oncol. 2022 Jan;6:e2100400. doi: 10.1200/PO.21.00400.

Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma 
With a Novel ALK-KANK4 Gene Fusion.

Gaule M(1)(2), Pesoni C(1)(2), Quinzii A(1)(2), Zecchetto C(1)(2), Casalino 
S(1)(2), Merz V(2)(3), Contarelli S(2), Pietrobono S(2), Vissio E(4), Molinaro 
L(4), Manzin E(5), Volpatto R(5), Vellani G(5), Melisi D(1)(2).

Author information:
(1)Investigational Cancer Therapeutics Clinical Unit, Azienda Ospedaliera 
Universitaria Integrata, Verona, Italy.
(2)Digestive Molecular Clinical Oncology Research Unit, Università degli Studi 
di Verona, Verona, Italy.
(3)Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy.
(4)Pathology Unit, Department of Medical Sciences, University of Turin and Città 
della Salute e della Scienza Hospital, Turin, Italy.
(5)Medical Oncology Unit, ASL Torino 4, Turin, Italy.

DOI: 10.1200/PO.21.00400
PMCID: PMC8769132
PMID: 35005993 [Indexed for MEDLINE]

Conflict of interest statement: Valeria MerzConsulting or Advisory Role: Amgen 
Davide MelisiConsulting or Advisory Role: Baxter, Lilly, Evotec, Incyte, 
iOncturaResearch Funding: Shire, Celgene, Incyte, iOnctura, RocheNo other 
potential conflicts of interest were reported.